Experienced in Marginal Zone Lymphoma (MZL)

Dr. Owen A. O'connor

Oncology
41 E Post Rd, 
White Plains, NY 
Offers Telehealth
Experienced in Marginal Zone Lymphoma (MZL)
41 E Post Rd, 
White Plains, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Owen O'connor is an Oncologist in White Plains, New York. Dr. O'connor is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, and Anaplastic Large Cell Lymphoma.

His clinical research consists of co-authoring 129 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Marginal Zone Lymphoma (MZL).

Specialties
Oncology
Licenses
Internal Medicine in NY
Hospital Affiliations
White Plains Hospital Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

41 E Post Rd, White Plains, NY 10601

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Phase I/IIa Study of the Oral 5-Azacitidine in Combination With the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Patients With Relapsed and Refractory Lymphoid Malignancies
Phase I/IIa Study of the Oral 5-Azacitidine in Combination With the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Patients With Relapsed and Refractory Lymphoid Malignancies
Enrollment Status: Terminated
Publish Date: August 22, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
A Phase 1 Trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Enrollment Status: Completed
Publish Date: July 25, 2024
Intervention Type: Drug
Study Drug: Tinostamustine
Study Phase: Phase 1
Phase 1/2a Study of Anti-PD-L1 Monoclonal Antibody Durvalumab in Combination With Pralatrexate and Romidepsin, Oral 5-Aza and Romidepsin, Romidepsin Alone, or Oral 5-Azacitidine for Treatment of Patients With Relapsed and Refractory PTCL
Phase 1/2a Study of Anti-PD-L1 Monoclonal Antibody Durvalumab in Combination With Pralatrexate and Romidepsin, Oral 5-Aza and Romidepsin, Romidepsin Alone, or Oral 5-Azacitidine for Treatment of Patients With Relapsed and Refractory PTCL
Enrollment Status: Unknown
Publish Date: March 31, 2022
Intervention Type: Drug
Study Drugs: Durvalumab, Pralatrexate, Romidepsin, Azacitidine
Study Phase: Phase 1/Phase 2
A Phase 1 Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
A Phase 1 Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
Enrollment Status: Completed
Publish Date: May 19, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 3 Less Clinical Trials

129 Total Publications

Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium study.
Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium study.
Journal: British journal of haematology
Published: February 12, 2025
Similar Doctors
Elite in Marginal Zone Lymphoma (MZL)
Dr. Andrew D. Zelenetz
Oncology
Elite in Marginal Zone Lymphoma (MZL)
Dr. Andrew D. Zelenetz
Oncology

Memorial Hematology Lymphoma Group

530 E 74th St, 
New York, NY 
 (20.2 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrew Zelenetz is an Oncologist in New York, New York. Dr. Zelenetz is rated as an Elite provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma (MCL), and Diffuse Large B-Cell Lymphoma (DLBCL).

Elite in Marginal Zone Lymphoma (MZL)
Dr. Gilles A. Salles
Hematology Oncology | Hematology | Oncology
Elite in Marginal Zone Lymphoma (MZL)
Dr. Gilles A. Salles
Hematology Oncology | Hematology | Oncology

Memorial Hematology Lymphoma Group

1275 York Ave, 
New York, NY 
 (20.5 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gilles Salles is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Salles is rated as an Elite provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Bone Marrow Transplant, and Splenectomy.

Distinguished in Marginal Zone Lymphoma (MZL)
Dr. Carol S. Portlock
Oncology
Distinguished in Marginal Zone Lymphoma (MZL)
Dr. Carol S. Portlock
Oncology
1275 York Ave, 
New York, NY 
 (20.5 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances

Carol Portlock is an Oncologist in New York, New York. Dr. Portlock is rated as a Distinguished provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). Her top areas of expertise are Non-Hodgkin Lymphoma, Marginal Zone Lymphoma (MZL), Follicular Lymphoma, and Diffuse Large B-Cell Lymphoma (DLBCL).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. O'connor's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile